Lavipharm Acquires Flagyl from Sanofi: A Milestone in Antibiotic Healthcare
In a landmark deal, Lavipharm has obtained exclusive rights to Flagyl, a key antibiotic, from Sanofi. This partnership aims to broaden healthcare access and integrate Flagyl seamlessly into Lavipharm's growing therapeutic portfolio, enhancing global health outcomes.
Read More
